Although the protease that specifically cleaves M161Ag into MALP-2 has not been identified, the peptide sequence of MALP-2 is determined by Mass spectrometry as S- [2,3-bis(palmitoyl) propyl]cysteine (Pam2Cys) followed by 14 amino acids (5) ( Table   1 ). In fact, the TLR2 agonistic functions are conserved in a synthetic compound (herein referred to MALP-2f) (5) . This synthetic MALP-2 has been applied to clinical phase studies to develop a new adjuvant (6) .
Several reports suggested that microbial pattern molecules have the ability to activate natural killer (NK) cells in vitro (7) (8) (9) (10) . TLR and cytoplasmic pattern sensors are representative pattern-recognition receptors (PRR) which may be associated with mDC-mediated NK activation (7) (8) (9) . TLR3 and the adaptor TICAM-1 (TRIF) in mDC typically participate in driving NK activation in response to dsRNA (10) . Recent studies on TLR2 agonists including lipopeptides also revealed that stimulation of TLR2 on mDC results in activation of the MyD88 pathway in mDC to drive external NK activation (11, 12) . NK cells play a role in early defense against various pathogens.
We have looked into the immuno-modulatory function of M161Ag and MALP-2, to develop a new adjuvant for cancer immunotherapy (1) . MALP-2 possessed high activity to induce IL-6, TNF-α, IL-10 and IL-12p40 from myeloid cells, but its functional potential for NK activation has not been examined yet. We test in the present studies whether MALP-2 has sufficient activity to induce NK cell activation in vitro and NK-mediated tumor regression in vivo using a mouse tumor implant model.
Materials and Methods

Reagents and antibodies
The following materials were obtained as indicated: Fetal calf serum (FCS) from Bio Whittaker (Walkersville, MD), mouse granulocyte-macrophage colony-stimulating factor (GM-CSF) from PeproTech EC, Ltd (London, UK), the enzyme-linked immunosorbent assay (ELISA) kits for mouse (m)IFN-γ from Biolegend (San Diego, CA), IL-12p40 and IL-6 from eBioscience (San Diego, CA). Two forms of synthetic macrophage-activating lipopeptide 2 (MALP-2) were ordered to Biologica Co., Nagoya,
4
Japan.
MALP-2s: Pam2CGNNDE (MW; 1201.5) and MALP-2f:
Pam2CGNNDESNISFKEK (MW; 2135.6). The synthesis of lipopeptides was achieved with a combination of solution-and solid-phase methods as described (13) . Pam2Cys12
(Pam 2 CSTSEVIGEKI), Pam2CSK4 (Pam 2 CSKKKK) and control Pam2CSK were prepared as referenced (12) . Poly I:C, a TLR3 agonist for induction of antitumor immunity, was used for this study as a positive control.
The following antibodies were used: fluorescein isothiocyanate (FITC)-labeled anti-mouse CD69, I-Ab, IFN-γ mAb, phycoerythrin (PE)-labeled anti-mouse CD86, CD25, and allophycocyanin (APC)-labeled anti-mouse NK1.1 were purchased from Biolegend (San Diego, CA).
Mouse and cell lines
TLR2 -/-and MyD88 -/-mice were gifts from Dr. S. Akira (Osaka Univ., Osaka) as previously reported (14) . Female C57BL/6 mice were purchased from Clea Japan (Tokyo).
Mice were maintained in our institute under specific pathogen-free conditions. All animal work was performed under guidelines established by the Hokkaido University Animal
Care and Use Committee. Mice (12 weeks female C57BL/6) were housed four per cage and allowed food and water ad libitum. Animal studies were carefully performed without ethical problems.
HEK293 cells were obtained from ATCC and maintained in RPMI 1640/10% FCS.
B16D8 cells were established in our laboratory as a subline of the B16 melanoma cell line (15) and cultured in RPMI 1640/10% FCS. This subline was characterized by its low MHC levels with no metastatic properties when injected s.c. into syngeneic C57BL/6 mice. The B16D8 cell line is a typical NK target (10).
Preparation of BMDC and spleen NK cells of mice
Mouse bone marrow-derived DC (BMDC) were prepared as described previously (16) .
Spleen NK cells were positively isolated from spleens with DX5 Micro Beads kit (Miltenyi Biotech) (10) . The purity of NK cells (DX5 + cells) was routinely about 80%. DX5 + NK cells were used within 24 h.
Reporter assay
Plasmids (pEFBos) for expression of human TLR1, TLR2, TLR6 and TLR10 were prepared in our laboratory as described previously (16) . HEK293 cells were seeded onto 24-well plates and transfected with various amounts of expression vectors, the ELAM reporter gene, and the phRL-TK control plasmid using FuGene HD (Roche) according to the manufacturer's instructions. After 24 h, the cells were harvested in 50 µl lysis buffer.
The luciferase activity was measured using Dual-Luciferase Reporter assay systems (Promega) and was shown as the means ± S.D. of three experiments.
ELISA, Flow cytometric (FACS) analysis of cell surface antigens
The levels of cytokines (IL-6, IL-12p40, IFN-γ etc.) were determined by sandwich ELISA (Amersham Pharmacia Biotech, Buckinghamshire, UK) or the message levels assessed by quantitative PCR (27) . Surface CD86 and I-Ab were determined by FACS using specific mAbs. The practical methods for FACS were described previously (16).
Assessment of in vitro cytolytic activity
The cytolytic activity of spleen NK cells was determined by 51 Cr assay as described previously (10) . NK cells were prepared from the spleen of C57BL/6 mice. NK cells were co-cultured with BMDCs at a ratio of 2:1 and 24 hrs later the mixtures were subdivided to assess NK-mediated cytotoxicity (10) . A B16 subline (D8) was used as a target cell. injected around tumor at day 0, 3, 7, 9, 13, and 17. Tumor surfaces were measured twice a week by using a caliper.
Results
BMDC maturation and cytokine liberation in response to MALP-2
Pam2Cys-containing lipopeptides, Pam2Cys12, Pam2CSK, Pam2CSK4, and two forms of MALP-2 (s and f) were synthesized with reference to a previous report (Fig. S1) 6 6 (13,17). Pam2CSK was used as a negative control (17) , which has virtually no cytokine-inducing activity ( Fig. 1) . By ELAM reporter assay, we assessed NF-κB activation potential of these lipopeptides (10~500 nM), and confirmed that all except Pam2CSK possess similar luciferin-activating potentials (data not shown).
IL-6 and IL-12p40 levels were determined by ELISA with the supernatant of the media where BMDC and each of the lipopeptides were co-cultured for 24 hrs. These cytokines were detected with high levels in the wells with Pam2Cys12, Pam2CSK4, MALP-2s and MALP-2f but not in Pam2CSK (Fig. 1A,B) . These lipopeptides neither induced the mRNA of type I interferon (IFN), IL-15 and I-18 (data not shown) nor produced less than the detection limit (<5 pg/ml) of IL-12p70 protein (Fig 1C) .
The degrees of CD86 upregulation were examined with the these lipopeptides, and similar DC maturation was evaluated by flow cytometry (Fig. 1D,E) . Although the levels of CD86 were increased in response to Pam2 peptides (100 nM), no significant difference was observed among the Pam2 peptides tested (Fig. 1E) . At the dose of Pam2 where cytokine induction sufficiently occurs, CD86 expression inadequately takes place in BMDC, as reported previously (12) . Thus, NF-κB activation, cytokine liberation and DC maturation are partially co-related in these lipopeptides.
NK activation by Pam2CSK4 and MALP-2
Previous reports suggested that TLR2 agonists have ability to induce NK activation (11, 12) . To investigate whether the mycoplasma lipopeptides harbor activity of NK cell activation, we added the Pam2Cys peptides (100 nM) to BMDC, NK cells or BMDC/NK co-culture as in a previous method assessing polyI:C activity for BMDC-mediated NK activation (10) . Although BMDC per se can induce IFN-γ production in response to some TLR stimuli (17, 18) , we could detect only minure amounts of IFN-γ in our setting using Pam2 lipopeptides ( Fig. 2A) . In this context, three markers for NK activation (19) were assessed with this system, IFN-γ production, up-regulation of NK activation markers and target cell (B16D8) cytotoxicity by NK cells (Fig. 2) . IFN-γ was generated in the supernatants (sup) of NK cells (Fig. 2B) or BMDC/NK coculture (Fig. 2C, Fig. 3A 
Participation of TLR2/MyD88 in MALP-2-mediated NK activation
We next examined whether the lipopeptide-mediated IFN-γ secretion was dependent on MyD88 of BMDC. IFN-γ secretion was almost completely abrogated in the co-culture with MyD88-/-BMDC and wild-type NK cells in the presence of Pam2Cys12 and Pam2CSK4 (Fig. 3A) , Similar tendencies were observed with MALP-2 peptides, which essentially evoked a minimal IFN-γ production, and the IFN-γ-induction was largely abrogated with MyD88-/-BMDC (Fig. 3A) . The results were less prominently reproduced with TLR2-/-BMDC and wild-type NK cells (data not shown). Further confirmation was performed using the mixtures with wild-type NK cells and various
lipopeptides. No direct activation of NK cells was observed in the absence of BMDC (data not shown).
The results were further confirmed with NK cytotoxic assay using NK cells cocultured with Pam2Cys lipopeptide-stimulated BMDC (Fig. 3B) . When wild-type BMDC was used as a NK cell cytotoxicity inducer, full NK activation was induced by Pam2Cys12 or Pam2CSK4. MALP-2f and s were found to be inefficient NK activators (Fig. 3B) . If wild-type BMDC were replaced with MyD88-/-BMDC, BMDC-enhanced NK cytotoxicity was abrogated (Fig. 3B) . The MyD88 pathway in BMDC is crucial for BMDC-mediated NK cell activation. 
